
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Author(s) -
Laura J. Esserman,
Donald A. Berry,
Maggie C.U. Cheang,
Christina Yau,
Charles M. Perou,
Lisa A. Carey,
Angela De Michele,
Joe W. Gray,
Kathleen Conway-Dorsey,
Marc E. Lenburg,
Meredith Buxton,
Sarah E. Davis,
Laura J. Van’t Veer,
Clifford A. Hudis,
Koei Chin,
Denise M. Wolf,
Helen Krontiras,
Leslie D. Montgomery,
Debu Tripathy,
Constance D. Lehman,
Minetta C. Liu,
Olufunmilayo I. Olopade,
Hope S. Rugo,
John T. Carpenter,
Chad Livasy,
Lynn G. Dressler,
David C. Chhieng,
Baljit Singh,
Carolyn Mies,
Joseph T. Rabban,
Yunni Yi Chen,
Dilip Giri,
Alfred Au,
Nola M. Hylton
Publication year - 2012
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/cbv3-3753
Subject(s) - oncology , breast cancer , medicine , biomarker , chemotherapy , neoadjuvant therapy , cancer , biology , biochemistry